Test your business idea: Flemingsberg Science Award Startup open for applications

STARTUP is a competition for startups with a clear connection to Flemingsberg, either as students, residents or otherwise active in the area.

All ideas are welcome to participate in STARTUP as long as you compete with your own idea and the turnover and external equity is below SEK 1,000,000 at the time you submit to the competition. After that, we of course welcome you to continue working with the business idea, sales and any investments.

The competition closes March 7.

Read more.

The Flemingsberg Science Award is a sub-competition to the national business plan competition Venture Cup. Venture Cup was launched in 1998 to support growth in Sweden. Since then, the concept has grown to include a successful process where participants receive help to develop their business ideas for tomorrow’s companies. Knowledgeable industry experts engage non-profit by providing feedback and development tips on all ideas submitted. In addition, the organization offers inspiration, training, guidance and the opportunity to create a solid network.

Read more about Venture Cup

Portabel Health: Crowned Winner of Flemingsberg Science STARTUP Award 2025

Quickly finding the right personnel is one of the healthcare sector’s major challenges, especially in times of staff shortages and increasing demands for efficiency. Portabel Health offers a modern solution to these problems through a digital platform that makes it easy for care providers to access qualified nurses and healthcare professionals.

Press Start: The Game Hub in Flemingsberg – Finally!

On April 24th, after just two months of hard work, it was finally time for the kick-off for the game cluster Press Start. The initiative is led by Drivhuset, in close collaboration with Flemingsberg Science Foundation and Södertörn University's Innovation Station.

AlzeCure Pharma – a hope in the fight against Alzheimer’s

Neurological diseases and the pain area are struggling with great medical needs, including the lack of broad-spectrum drugs. Those are gaps in the market that AlzeCure Pharma wants to fill, and they are well on their way. They recently received a grant from the European Innovation Council (EIC) to finance a clinical phase 2 study of the drug candidate NeuroRestore ACD856 for Alzheimer’s disease.

Do you want to know more?
Subscribe to our newsletter.

Do you want to know more?
Subscribe to our newsletter.

CF_logo_neg
2023-01-30T11:15:12+01:00
Go to Top